Abstract
ObjectivesTo estimate the cost-effectiveness of ranolazine when added to standard-of-care (SoC) antianginals compared with SoC alone in patients with stable coronary disease experiencing ≥3 attacks/week.SettingAn economic model utilising a UK...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have